Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.01B | 4.80B | 4.29B | 3.71B | 3.21B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.01B | 4.80B | 4.29B | 3.71B | 3.21B |
| Cost of Revenue | 1.14B | 977.45M | 821.95M | 681.87M | 516.97M |
| Gross Profit | 3.87B | 3.83B | 3.46B | 3.03B | 2.69B |
| SG&A Expenses | 1.34B | 1.32B | 1.29B | 1.21B | 1.18B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.04B | 3.80B | 3.53B | 3.21B | 2.95B |
| Operating Income | 977.59M | 999.78M | 752.14M | 501.58M | 264.70M |
| Income Before Tax | 856.41M | 841.16M | 622.05M | 398.03M | 42.93M |
| Income Tax Expenses | -1.87B | -8.42M | 9.18M | 9.41M | -75.51M |
| Earnings from Continuing Operations | 2.72K | 849.59 | 612.87 | 388.62 | 118.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.72B | 849.59M | 612.87M | 388.62M | 118.44M |
| EBIT | 977.59M | 999.78M | 752.14M | 501.58M | 264.70M |
| EBITDA | 1.03B | 1.05B | 806.94M | 557.24M | 321.02M |
| EPS Basic | 20.39 | 6.42 | 4.63 | 2.94 | 0.88 |
| Normalized Basic EPS | 3.83 | 3.97 | 2.94 | 1.89 | 0.38 |
| EPS Diluted | 19.80 | 6.23 | 4.47 | 2.82 | 0.80 |
| Normalized Diluted EPS | 3.70 | 3.82 | 2.82 | 1.81 | 0.31 |
| Average Basic Shares Outstanding | 532.56M | 530.18M | 527.20M | 523.98M | 520.87M |
| Average Diluted Shares Outstanding | 550.83M | 550.14M | 542.48M | 533.93M | 526.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |